Aradigm Corporation (OTC PINK: ARDM) is a specialty pharmaceutical company focused on development and commercialization of products for the treatment and prevention of severe respiratory diseases. having gone public before they became SBIRInvolved, the firm's lead development candidates are proprietary formulations of the potent antibiotic ciprofloxacin, including Linhaliq and Lipoquin that are delivered by inhalation for the management of infections associated with severe respiratory diseases, including non-cystic fibrosis bronchiectasis, cystic fibrosis, and non-tuberculosis mycobacterium. The company is also developing inhaled ciprofloxacin formulations for treatment of patients with cystic fibrosis, and has tested for the prevention and treatment of inhaled bioterrorism infections, such as oxiella burnetii or Q fever, inhalation anthrax, tularemia, melioidosis and pneumonic plague.
